This publication was downloaded for exclusive use by: Aiman.Mohamad@macquarie.com

Flashnote 24 November 2020

EQUITIES

MRC MK Price (at 15:29, 23 Nov 2020 GMT)	O	utperform RM0.47
Valuation	RM	0.70
- DCF (WACC 8.4%, beta 1.2, E	RP 6.5%, RF	R 4.5%)
12-month target	RM	0.70
Upside/Downside	%	+50.5
12-month TSR	%	+52.6
Volatility Index		High
GICS sector	Ca	pital Goods
Market cap	RMm	2,052
Market cap	US\$m	501
Free float	%	45
30-day avg turnover	US\$m	0.7
Number shares on issue	m	4,412

Investment fundamentals

Year end 31 Dec		2019A	2020E	2021E	2022E
Revenue	m	1,319.4	1,157.2	2,032.0	2,522.6
EBITDA	m	134.1	107.1	174.2	216.3
EBIT	m	72.4	66.3	134.5	175.6
Reported profit	m	23.7	40.0	115.3	138.7
Adjusted profit	m	23.7	40.0	115.3	138.7
EPS rep	sen	0.5	0.9	2.6	3.2
EPS rep growth	%	-76.5	68.6	187.9	20.4
EPS adj	sen	0.5	0.9	2.6	3.2
EPS adj growth	%	-68.5	68.6	187.9	20.4
PER rep	х	85.9	51.0	17.7	14.7
PER adj	х	85.9	51.0	17.7	14.7
Total DPS	sen	1.0	0.8	1.0	1.5
Total DPS growth	%	-20.0	-25.0	33.3	50.0
Total div yield	%	2.2	1.6	2.2	3.2
ROA	%	0.9	0.8	1.5	1.8
ROE	%	0.5	0.8	2.4	2.8
EV/EBITDA	х	23.8	24.0	13.4	11.2
Net debt/equity	%	27.2	37.1	41.1	46.6
P/BV	х	0.4	0.4	0.4	0.4

MRC MK rel KLCI performance, & rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period Source: FactSet, Macquarie Research, November 2020 (all figures in MYR unless noted)

Malaysia

MRCB (MRC MK) Results miss: losses narrowed in 3Q20

Event

• MRCB's 9M20 adj. loss registered at RM5.6m (-132% YoY) missing our estimates at -14% of FY20E, but in-line with consensus estimates at 74%. Consensus expects a loss in FY20E, while we forecast a FY20E profit of RM40m - resulting in the miss. Revenue in 9M20 was at RM891m tracking inline with MQ estimates at 77% but behind consensus estimates at 69%. However MRCB reported an adj. PAT of RM0.9mn (-64% YoY, >+100% QoQ) in 3Q20 as operations began to contribute profit post-lockdown.

Impact


- Construction orderbook progressing slowly; we hope new projects will be strong revenue drivers for the division. MRCB's outstanding orderbook stood at RM20.546bn as of 3Q20-end; not much has changed since the RM20.694bn orderbook balance in 2Q20 - this shows that construction orderbook is pretty idle and it needs an injection of new projects to drive this division's revenue.
- Property sales remain slow, but inventory dropped by 6.6% QoQ. As of 9M20, MRCB recorded only RM126m of pre-sales, with RM40m contributed in 3Q20 alone. Inventory dipped by 6.6% QoQ to RM498m in 3Q20 driven by sales from 1060 Canergie project in Australia, which contributed directly to MRCB's revenue. Launched projects plus the outstanding inventory stand at RM867m and management will continue to limit new launches and focus on reducing the available units for sale in the coming quarters.
- Arbitration with George Kent is now ongoing. According to management, the arbitration process on the ultimate owner of the LRT3 turnkey contractor role is now ongoing. MRCB believes that it has better grounds to emerge as the sole main contractor as it has better financial backing and expertise to run the project.
- Our thoughts: We have highlighted that MRCB has been facing execution • issues in the engineering and construction division, where close to 70% of its orderbook consists of idle projects. On order wins, we are confident that MRCB will secure the waste-to-energy projects in the central region, which may bring an additional RM2bn of new order wins (plus concession contract) for MRCB over the next 12 months. However if MRCB is not able to secure new projects, particularly the WTE concession contracts, this would be the key downside risk of the company.

MRCB 9M20 results summary

RM 'mil	Actual 9M20	Macquarie FY20	% of F20E	Consensus FY20E	% of F20E
Revenue	891	1,157	77%	1,286	69%
EBIT	24	66	36%	81	30%
PBT	-188	58	-324%	9	-2098%
Adj. PAT	-6	40	-14%	-8	74%

Source: Bloomberg, Company data, Macquarie Research, November 2020

Analysts



Aiman Mohamad +60 3 2059 8986 aiman.mohamad@macquarie.com

Action and recommendation

• Our investment opinions on the company are under review.

Macquarie Research

Important disclosures:

Recommendation definitions

Macquarie – Asia and USA Outperform – expected return >10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie – Australia/New Zealand

Outperform – expected return >10% Neutral – expected return from 0% to 10% Underperform – expected return <0%

Note: expected return is reflective of a Medium Volatility stock and should be assumed to adjust proportionately with volatility risk

Volatility index definition*

This is calculated from the volatility of historical price movements.

Very high-highest risk – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.

High – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.

Medium – stock should be expected to move up or down at least 30–40% in a year.

Low-medium – stock should be expected to move up or down at least 25–30% in a year.

Low – stock should be expected to move up or down at least 15–25% in a year. * Applicable to select stocks in Asia/Australia/NZ

Recommendations - 12 months

Note: Quant recommendations may differ from Fundamental Analyst recommendations

Recommendation proportions - For quarter ending 30 Sept 2020

	AU/NZ	Asia	USA	
Outperform	56.27%	63.55%	63.04%	(for global coverage by Macquarie, 4.95% of stocks followed are investment banking clients)
Neutral	29.49%	21.61%	36.96%	(for global coverage by Macquarie, 4.25% of stocks followed are investment banking clients)
Underperform	14.24%	14.84%	0.00%	(for global coverage by Macquarie, 2.37% of stocks followed are investment banking clients)

MRC MK vs KLCI, & rec history



Note: Recommendation timeline – if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, November 2020

12-month target price methodology

MRC MK: RM0.70 based on a Sum of Parts methodology

Company-specific disclosures:

MRC MK: Macquarie may be an Issuer of Structured Warrants on securities mentioned in this report

Important disclosure information regarding the subject companies covered in this report is available publicly at

www.macquarie.com/research/disclosures. Clients receiving this report can additionally access previous recommendations (from the year prior to publication of this report) issued by this report's author at https://www.macquarieinsights.com.

Date	Stock Code (BBG code)	Recommendation	Target Price
10-Jul-2020	MRC MK	Outperform	RM.70
13-Mar-2020	MRC MK	Neutral	RM.50
06-May-2019	MRC MK	Outperform	RM1.20
02-Feb-2019	MRC MK	Outperform	RM.90
26-Jul-2018	MRC MK	Outperform	RM1.00
30-Apr-2018	MRC MK	Outperform	RM1.25

Target price risk disclosures:

MRC MK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

Sensitivity analysis:

Clients receiving this report can request access to a model which allows for further in-depth analysis of the assumptions used, and recommendations made, by the author relating to the subject companies covered. To request access please contact <u>insights@macquarie.com</u>. Analyst certification:

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities. General disclaimers:

Financial definitions

adjustments made:

minority interests

number of shares

Reporting Standards).

total assets

All "Adjusted" data items have had the following

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging,

Excluded: non recurring items, asset revals, property

revals, appraisal value uplift, preference dividends &

ROE = adjusted net profit / average shareholders funds

Gross cashflow = adjusted net profit + depreciation

All Reported numbers for Australian/NZ listed stocks

*equivalent fully paid ordinary weighted average

are modelled under IFRS (International Financial

IFRS impairments & IFRS interest expense

ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average

EPS = adjusted net profit / efpowa*

Macquarie Research

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited, Taiwan Securities Branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, guantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Members of the Macro Strategy team are Sales & Trading personnel who provide desk commentary that is not a product of the Macquarie Research department or subject to FINRA Rule 2241 or any other regulation regarding independence in the provision of equity research.

Country-specific disclaimers:

Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organization of the Australian Securities Exchange. Macquarie Securities (Australia) Limited staff involved with the preparation of research have regular interaction with companies they cover. Additionally, Macquarie Group Limited does and seeks to do business with companies covered by Macquarie Research. There are robust information barriers in place to protect the independence of Macquarie Research's product. However, recipients of Macquarie Research should be aware of this potential conflict of interest. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. United Kingdom and the EEA: In the United Kingdom and the European Economic Area, research is distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. During the past 12 months, Macquarie Group Limited or one of its affiliates may have provided securities services to companies mentioned in this report for which it received compensation for Broking services. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 199801007342 (463469-W)) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: In Taiwan, research is issued and distributed by Macquarie Capital Limited, Taiwan Securities Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. The recipient of this report shall not engage in any activities which may give rise to potential conflicts of interest to the report. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Macquarie may be in past one year or now being an Issuer of Structured Warrants on securities mentioned in this report. Thailand: In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thaiiod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie

<u>iod.com/en/publications.asp?type=4</u>. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at <u>http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId=</u>

MDIS0300200100000&serviceld=SDIS03002001000. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. Singapore recipients should contact Macquarie Capital Securities (Singapore) Pte Ltd at +65 6601 0888 for matters arising from, or in connection with, this report. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report

www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Capital (USA) Inc, 125 W.55th Street, New York, NY 10019. **Canada**: In Canada, research is distributed by Macquarie Capital Markets Canada Ltd., a (i) member of the Investment Industry Regulatory Organization of Canada (IIROC) and the Canadian Investor Protection Fund, and (ii) participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures. IIROC Rule 3400 Disclosures can be obtained by writing to Macquarie Capital Markets Canada Ltd., 181 Bay St. Suite 3100, Toronto, ON M5J2T3. **Equities**

Asia Research

Head of Equity Research

Jake Lynch (Asia) Damian Thong (Japan) Jayden Vantarakis (ASEAN)

Strategy, Country

Viktor Shvets (Asia, Global)	(852) 3922 3883
David Ng (China, Hong Kong)	(852) 3922 1291
Damian Thong (Japan)	(813) 3512 7877
Daniel Kim (Korea)	(822) 3705 8641
Jeffrey Ohlweiler (Taiwan)	(8862) 2734 7512
Jayden Vantarakis	
(ASEAN, Singapore)	(6221) 2598 8310
Ari Jahja (Indonesia)	(6221) 2598 8366
Prem Jearajasingam (Malaysia)	(603) 2059 8989
Gilbert Lopez (Philippines)	(632) 857 0892
Peach Patharavanakul (Thailand)	(662) 694 7753
Aditya Suresh (India)	(852) 3922 1265
Charles Yonts (Asia ESG)	(852) 3922 5832
Felix Rusli (Asia Product)	(852) 3922 4283

Technology

Nicolas Baratte (Asia)
Damian Thong (Asia)
Jeffrey Ohlweiler (Greater China)
Cherry Ma (Greater China)
Erica Chen (Greater China)
Kaylin Tsai (Greater China)
Hiroshi Taguchi (Japan)
Daniel Kim (Korea)
Sonny Lee (Korea)
Abhishek Bhandari (India)

Telecoms

Nicolas Baratte (Asia) Hiroshi Yamashina (Japan) Andy Kim (Korea) Prem Jearajasingam (ASEAN) Kervin Sisayan (Philippines)

Internet, Media and Software

(852) 3922 5926
(852) 3922 3578
(852) 3922 1433
(852) 3922 4110
(813) 3512 5968
(822) 3705 8690
(9122) 6720 4134

Sales)

Consumer, Gaming

(852) 3922 3583

(813) 3512 7877

(852) 3922 5801

(813) 3512 5968

(822) 3705 8690

(603) 2059 8989

(632) 857 0893

(6221) 2598 8310

consumer, Gaining	
Linda Huang (Asia) Terence Chang (China, Hong Kong) Sunny Chow (China, Hong Kong) Edward Engel (China, Hong Kong) Leon Rapp (Japan) Karisa Magpayo (Philippines) Chalinee Congmuang (Thailand)	(852) 3922 4068 (852) 3922 3581 (852) 3922 3768 (852) 3922 5750 (813) 3512 7879 (632) 857 0899 (662) 694 7993
Healthcare and Pharmaceuti	cals
David Ng (China, Hong Kong) Mi Hyun Kim (Korea) Ari Jahja (Indonesia) Bo Denworalak (Thailand) Alankar Garude (India)	(852) 3922 1291 (822) 3705 8689 (6221) 2598 8366 (662) 694 7774 (9122) 6720 4134
Banks and Financials	
Scott Russell (Asia) Dexter Hsu (China, Taiwan) Suresh Ganapathy (India) Nishant Shah (India) Jayden Vantarakis (ASEAN, Indonesia, Singapore) Ben Shane Lim (Malaysia) Gilbert Lopez (Philippines) Peach Patharavanakul (Thailand)	(852) 3922 3567 (8862) 2734 7530 (9122) 6720 4078 (9122) 6720 4099 (6221) 2598 8310 (603) 2059 8868 (632) 857 0892 (662) 694 7753
Property, REIT	
Kelvin Tam (China, Hong Kong) Masahiro Mochizuki (Japan) Richard Danusaputra (Indonesia) Aiman Mohamad (Malaysia) Kervin Sisayan (Philippines) Derrick Heng (Singapore) Bo Denworalak (Thailand) Abhishek Bhandari (India)	(852) 3922 1181 (813) 3512 7868 (6221) 2598 8368 (603) 2059 8986 (632) 857 0893 (65) 6601 0436 (662) 694 7774 (9122) 6720 4088

Oil, Gas and Petrochemicals

Mark Wiseman (A Anna Park (Asia) Yasuhiro Nakada Ben Shane Lim (I Yupapan Polporn Aditya Suresh (In	(Japan) Malaysia) prasert (Thailand)	(612) 8232 8417 (822) 3705 8669 (813) 3512 7862 (603) 2059 8868 (662) 694 7729 (852) 3922 1265
Basic Materia	als, Commoditie	s
David Ching (Chi Yasuhiro Nakada Anna Park (Korea Ashish Jain (India	(Japan) a)	(852) 3922 1823 (813) 3512 7862 (822) 3705 8669 (9122) 6720 4063
Mobility, Auto	omation, Industr	ials
James Hong (Asi Eric Zong (China, Allen Yuan (China Kunio Sakaida (Ja Zhiwei Foo (Singa Arya Sen (India) Ajinkya Bhat (Ind	(822) 3705 8661 (852) 3922 4749 (8621) 2412 9009 (813) 3512 7873 (65) 6601 0465 (9122) 6720 4010 (9122) 6720 4052	
Utilities, Ren	ewables	
Mark Wiseman (China, Hong Kong) Kerry Cheng (China, Hong Kong) Karisa Magpayo (Philippines)		(612) 8232 8417 (8621) 2412 9025 (632) 857 0899
Find our rese Macquarie: Refinitiv: Bloomberg: Factset: CapitallQ	sights.com com/home.aspx	

Contact macresearch@macquarie.com for access requests.

Email addresses

FirstName.Surname@macquarie.com

Asia Sales

Regional Heads of Sales

Christina Lee (Head of Asian
Alan Chen (HK/China)
Amelia Mehta (Singapore)
Paul Colaco (US)
Mothlib Miah (UK/Europe)
Anjali Sinha (India)
Janeman Latul (Indonesia)
Thomas Renz (Geneva)
Leslie Hoy (Japan)

(1 212) 231 2559 (852) 3922 2019 (65) 6601 0211 (1 415) 762 5003 (44 20) 3037 4893 (9122) 6653 3229 (6221) 2598 8303 (41 22) 818 7712 (813) 3512 7919

Regional Heads of Sales cont'd

Tomohiro Takahashi (Japan) DJ Kwak (Korea) Nik Hadi (Malaysia) Gino C Rojas (Philippines) Richard Liu (Taiwan) Angus Kent (Thailand)

(813) 3512 7823 (822) 3705 8608 (603) 2059 8888 (632) 857 0861 (8862) 2734 7590 (662) 694 7601

Sales Trading

Mark Weekes (Asia)	(852) 3922 2084
Sacha Beharie (HK/China)	(852) 3922 2111
Susan Lin (Taiwan)	(8862) 2734 7583
Edward Jones (Japan)	(813) 3512 7822
Douglas Ahn (Korea)	(822) 3705 9990
Stanley Dunda (Indonesia)	(6221) 515 1555
Suhaida Samsudin (Malaysia)	(603) 2059 8888
Michael Santos (Philippines)	(632) 857 0813
Justin Morrison (Singapore)	(65) 6601 0288
Brendan Rake (Thailand)	(662) 694 7707
Alex Johnson (India)	(9122) 6720 4022
Mike Gray (New York)	(1 212) 231 2555
Mike Keen (UK/Europe)	(44 20) 3037 4905